Aug 4, 2009 - Progenics Pharmaceuticals, Inc. and Wyeth Pharmaceuticals, today announced submission of a supplemental New Drug Application (sNDA) to the U.S.FDA and an Extension Application to the European Union (E.U.) European Medicines Agency (EMEA) for RELISTOR® (methylnaltrexone bromide) subcutaneous injection for a new delivery system, pre-filled syringes.
The details can be read here.
No comments:
Post a Comment